Drugs / Pyridorin
Pyridorin
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05083546 | Dec 2024 → Dec 2025 | obesity disorder | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00734253 | Aug 2008 → Aug 2010 | diabetic kidney disease | NephroGenex, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00490113 | Jan 2007 → ? | urolithiasis | University of Kansas Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00320021 | Jul 2002 → Sep 2003 | diabetic kidney disease | BioStratum | Completed | No outcome recorded |
| Phase 2 | NCT00320060 | Oct 2001 → Jan 2003 | diabetic kidney disease | BioStratum | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02156843 | Jun 2014 → Dec 2017 | diabetic kidney disease | NephroGenex, Inc. | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03778580 | Mar 2018 → Feb 2022 | type 2 diabetes mellitus | Columbia University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyridorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02156843 ↗ |
| Known as | Pyridoxamine | “MGO cocktail containing a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine” NCT05083546 ↗ |
| Known as | pyridoxamine dihydrochloride | “The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with...” NCT00320060 ↗3“Pyridorin (pyridoxamine dihydrochloride) 300 mg oral BID (twice daily, every 12 hours) Capsule” NCT02156843 ↗ “Pyridorin (pyridoxamine dihydrochloride)” NCT00320021 ↗ |
| Route | Oral | “250 mg given orally twice daily” NCT00320021 ↗ |